Full-Life Technologies

🚀 Major milestone: Our Partner SK Biopharmaceuticals’ NTSR1-targeted alpha therapy SKL35501 (in-licensed from Full-Life, previsouly FL-091) and imaging agent SKL35502 cleared for US Phase 1 trials. Highlights: ✔️ 18-month IND turnaround post-licensing ✔️ Validates Full-Life's end-to-end radiopharma capabilities Proud to fuel partner’s success.

🏆 Celebrating the Building Bridges Award 2025 in Suzhou! We are thrilled to share that Full-Life Technologies was honored with the Building Bridges Award 2025 at the prestigious Suzhou Building Bridges Networking Events. Julie Wu, President and CFO, accepted the award on behalf of the company. This wonderful recognition highlights our active role in fostering Belgium-China collaboration within the radiopharmaceutical sector. The event underscored the power of international partnerships — a core value at Full-Life as we continue to integrate our operations in Belgium, including our state-of-the-art facility in Gembloux, with the dynamic innovation ecosystem in China. #FullLifeTechnologies #BuildingBridges #BelgiumChinaCollaboration #Radiopharmaceuticals

Full-Life's Belgium manufacuturing facility is to be up & running soon! Come with Philippe van Put to see the latest progress!

🕵♀️ Series C led by Junson Capital along with new investor syndicate and existing shareholders 💰 Funding will further advance Full-Life's global radiopharmaceutical pipeline and manufacturing capabilities in Belgium 🏦 Additional debt financing provides an alternative financing solution for Full-Life’s future development https://lnkd.in/ehRs_PA2

Join Full-Life at EANM 2025 📍 Barcelona | 📅 Oct 4 – 8 Meet our leadership team onsite: 👔 Lanny Sun, CEO 🎗️ Debora Barton, MD 🎗️, CMO 🔬 Fa Liu, CSO 🏗 Philippe van Put, General Manger Europe Connect with us to explore collaboration of precision radiopharmaceuticals!

Join Full-Life at BIO International Convention 2025 📍 Boston | 📅 June 16–19 Meet our leadership team on-site: 👔 Lanny Sun, CEO 🎗️ Debora Barton, MD 🎗️, CMO 🔬 Fa Liu, CSO Connect with us to explore collaborations, innovations, and the future of precision radiopharmaceuticals!

Full-Life will participate in the ASCO 2025 Annual Meeting and deliver a poster presentation about ongoing global phase 1 clinical trial of our lead asset, [225Ac]Ac-FL-020, on June 2nd 9 AM CT. Our CMO, Debora Barton, MD 🎗️ looks forward to speaking with you on the site!

https://lnkd.in/eV7PZj8C Welcome to Full-Life! @Debora Barton, MD “We are thrilled to welcome Dr. Barton to Full-Life at this pivotal moment as we ramp up to bring multiple assets into global phase 1 trials. Her unparalleled expertise in radiopharmaceutical clinical development, demonstrated through multiple successful regulatory approvals and clinical program executions, makes her the ideal leader for this critical phase of our growth. As our new Chief Medical Officer, Dr. Barton's strategic vision and innovative approach will be invaluable assets to our team.” Said Lanny Sun, Co-founder, Chairman and CEO of Full-Life Technologies.

Full-Life Technologies will present preclinical data of its promising early pipeline FL-031 and FL-801 at the American Association for Cancer Research (AACR) 2025 Annual Meeting. Dr. Fa Liu, Chief Scientific Officer, will give two poster presentations on April 27, 2025, 2:00 PM CDT.   We look forward to speaking with you on the site! #AACR25